|
|
|
|
|
by hyrix
685 days ago
|
|
They stopped the study because of the incredible efficacy and lack of side effects. This was a phase 3 clinical trial so they have already cleared substantial hurdles in safety requirements (clinical trials are about both efficacy and side effects). But for argument’s sake, there are even more sides than efficacy and safety: there are substantially different risk profiles for different potential patients, and a long acting treatment with no daily pill is more valuable for some people. One of the reasons that long acting injectables could have a big impact on transmission in Africa is because there’s stigma around PrEP usage, especially for women. Obviously, there is now a big conversation about the cost and who pays, but the potential here is indisputable. https://www.niaid.nih.gov/news-events/nih-statement-prelimin... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10879468/ |
|
Are you aware that historically when this has happened, it almost always turns out to have negative side effects and marginal efficacy?
Don't you think an easy con is to flip a coin 3 times, and if you get heads all 3 times, tell everyone it always comes up heads, and there's no need to continue to measure it, but just to trust them?